<p>MiNK Therapeutics, Inc. ((INKT)) 举行了第三季度财报电话会议。请继续阅读会议的主要亮点。</p>
<h3>认识您的 ETF AI 分析师</h3>
<ul>
<li>了解 TipRanks 的 <em>ETF</em> AI 分析师如何帮助您做出更明智的投资决策</li>
<li>探索 TipRanks 用户喜爱的 ETF，并查看 <strong><em>ETF</em> AI 分析师</strong> 对您关注的 ETF 的见解。</li>
</ul>
<p>MiNK Therapeutics, Inc. 最近的财报电话会议充满了积极的情绪，主要得益于临床试验的显著成就、战略合作以及增强的制造能力。尽管报告的净亏损有所增加，但公司的强大财务战略和领导层增强了对其未来增长轨迹的信心。</p>
<h2>成功的临床试验和数据</h2>
<p>MiNK Therapeutics 展示了其正在进行的 AGENT-797 试验的良好结果，强调在重度预处理、免疫疗法耐药的实体肿瘤患者中，患者的中位总生存期约为 23 个月。该试验还报告了一名转移性睾丸癌患者的完全缓解，以及二线胃癌患者的持久部分缓解，突显了 AGENT-797 在挑战性癌症类型中的潜力。</p>
<h2>战略合作与资助</h2>
<p>该公司与威斯康星大学卡本癌症中心建立了战略合作关系，并获得了来自国防部和 NIH STTR 资助的重大公私合营资助。这些合作和财政支持对推动 MiNK 在移植物抗宿主病和干细胞移植方面的研究至关重要。</p>
<h2>制造和财务实力</h2>
<p>MiNK 显著增强了其制造能力，现在每位捐赠者可生产数十亿个细胞。在财务方面，公司保持了 1430 万美元的稳定现金余额，并通过额外的融资努力将其财务支持延续至 2026 年，确保对其创新项目的持续支持。</p>
<h2>领导层和董事会任命</h2>
<p>公司通过任命 Dr. John Holcomb 为董事会成员和 Dr. Terese Hammond 担任关键领导角色来加强其领导团队。这些任命预计将推动多个关键项目向前发展，利用他们的专业知识和愿景。</p>
<h2>净亏损增加</h2>
<p>MiNK 报告截至 2025 年 9 月 30 日的季度净亏损为 290 万美元，而去年为 180 万美元。这一增加反映了更高的运营费用，因为公司继续投资于 AGENT-797 项目的开发和支持。</p>
<h2>前瞻性指导</h2>
<p>展望未来，MiNK Therapeutics 正在为急性肺功能障碍的全球二期试验做准备，并推进其移植物抗宿主病研究。这些努力得到了公私合营伙伴关系和联邦资助的支持，突显了公司对扩展其治疗管线和满足未满足医疗需求的承诺。</p>
<p>总之，MiNK Therapeutics, Inc. 的财报电话会议传达了积极的前景，得益于成功的临床试验、战略合作和强大的领导力。尽管净亏损有所增加，但公司的财务战略和持续进展表明其创新疗法的未来充满希望。</p>

INKT

<p>MiNK Therapeutics 第三季度的财报电话会议强调了由于成功的临床试验、战略合作伙伴关系和增强的制造能力而带来的积极情绪。尽管净亏损增加至 290 万美元，公司仍保持稳定的现金余额，并计划未来的增长。关键领导职位的任命和公私合营伙伴关系支持持续的研发，预示着其创新疗法的光明未来</p>

<p>Mink Therapeutics, Inc. ((INKT)) has held its Q3 earnings call. Read on for the main highlights of the call.</p>
<div class="lb-trans"><p>MiNK Therapeutics, Inc. ((INKT)) 举行了第三季度财报电话会议。请继续阅读会议的主要亮点。</p>
</div><h3>Meet Your ETF AI Analyst</h3>
<div class="lb-trans"><h3>认识您的 ETF AI 分析师</h3>
</div><ul>
<li>Discover how TipRanks' <em>ETF</em> AI Analyst can help you make smarter investment decisions</li>
<li>Explore ETFs TipRanks' users love and see what insights the <strong><em>ETF</em> AI Analyst</strong> reveals about the ones you follow.</li>
</ul>
<div class="lb-trans"><ul>
<li>了解 TipRanks 的 <em>ETF</em> AI 分析师如何帮助您做出更明智的投资决策</li>
<li>探索 TipRanks 用户喜爱的 ETF，并查看 <strong><em>ETF</em> AI 分析师</strong> 对您关注的 ETF 的见解。</li>
</ul>
</div><p>The recent earnings call for MiNK Therapeutics, Inc. was marked by an overwhelmingly positive sentiment, driven by notable achievements in clinical trials, strategic collaborations, and enhanced manufacturing capabilities. Despite a reported increase in net loss, the company’s robust financial strategy and leadership instill confidence in its future growth trajectory.</p>
<div class="lb-trans"><p>MiNK Therapeutics, Inc. 最近的财报电话会议充满了积极的情绪，主要得益于临床试验的显著成就、战略合作以及增强的制造能力。尽管报告的净亏损有所增加，但公司的强大财务战略和领导层增强了对其未来增长轨迹的信心。</p>
</div><h2>Successful Clinical Trials and Data</h2>
<div class="lb-trans"><h2>成功的临床试验和数据</h2>
</div><p>MiNK Therapeutics showcased promising results from their ongoing trial of AGENT-797, highlighting a median overall survival of approximately 23 months in patients with heavily pretreated, immune therapy-resistant solid tumors. The trial also reported a complete remission in a patient with metastatic testicular cancer and a durable partial response in second-line gastric cancer, underscoring the potential of AGENT-797 in challenging cancer types.</p>
<div class="lb-trans"><p>MiNK Therapeutics 展示了其正在进行的 AGENT-797 试验的良好结果，强调在重度预处理、免疫疗法耐药的实体肿瘤患者中，患者的中位总生存期约为 23 个月。该试验还报告了一名转移性睾丸癌患者的完全缓解，以及二线胃癌患者的持久部分缓解，突显了 AGENT-797 在挑战性癌症类型中的潜力。</p>
</div><h2>Strategic Partnerships and Grants</h2>
<div class="lb-trans"><h2>战略合作与资助</h2>
</div><p>The company has forged strategic partnerships with the University of Wisconsin Carbone Cancer Center and secured significant public-private grants from the Department of Defense and NIH STTR awards. These collaborations and financial supports are pivotal in advancing MiNK’s research in graft-versus-host disease and stem cell transplantation.</p>
<div class="lb-trans"><p>该公司与威斯康星大学卡本癌症中心建立了战略合作关系，并获得了来自国防部和 NIH STTR 资助的重大公私合营资助。这些合作和财政支持对推动 MiNK 在移植物抗宿主病和干细胞移植方面的研究至关重要。</p>
</div><h2>Manufacturing and Financial Strength</h2>
<div class="lb-trans"><h2>制造和财务实力</h2>
</div><p>MiNK has significantly bolstered its manufacturing capabilities, now producing billions of cells per donor. Financially, the company maintains a stable cash balance of $14.3 million, with additional fundraising efforts extending their financial runway through 2026, ensuring continued support for their innovative programs.</p>
<div class="lb-trans"><p>MiNK 显著增强了其制造能力，现在每位捐赠者可生产数十亿个细胞。在财务方面，公司保持了 1430 万美元的稳定现金余额，并通过额外的融资努力将其财务支持延续至 2026 年，确保对其创新项目的持续支持。</p>
</div><h2>Leadership and Board Appointments</h2>
<div class="lb-trans"><h2>领导层和董事会任命</h2>
</div><p>The company has strengthened its leadership team with the appointment of Dr. John Holcomb to the Board of Directors and Dr. Terese Hammond in a key leadership role. These appointments are expected to drive several critical programs forward, leveraging their expertise and vision.</p>
<div class="lb-trans"><p>公司通过任命 Dr. John Holcomb 为董事会成员和 Dr. Terese Hammond 担任关键领导角色来加强其领导团队。这些任命预计将推动多个关键项目向前发展，利用他们的专业知识和愿景。</p>
</div><h2>Increased Net Loss</h2>
<div class="lb-trans"><h2>净亏损增加</h2>
</div><p>MiNK reported a net loss of $2.9 million for the quarter ended September 30, 2025, compared to $1.8 million in the previous year. This increase reflects higher operational expenses as the company continues to invest in the development and support of its AGENT-797 programs.</p>
<div class="lb-trans"><p>MiNK 报告截至 2025 年 9 月 30 日的季度净亏损为 290 万美元，而去年为 180 万美元。这一增加反映了更高的运营费用，因为公司继续投资于 AGENT-797 项目的开发和支持。</p>
</div><h2>Forward-Looking Guidance</h2>
<div class="lb-trans"><h2>前瞻性指导</h2>
</div><p>Looking ahead, MiNK Therapeutics is preparing for a global Phase two trial in acute pulmonary dysfunction and advancing their graft-versus-host disease study. These efforts are supported by public-private partnerships and federal grants, highlighting the company’s commitment to expanding its therapeutic pipeline and addressing unmet medical needs.</p>
<div class="lb-trans"><p>展望未来，MiNK Therapeutics 正在为急性肺功能障碍的全球二期试验做准备，并推进其移植物抗宿主病研究。这些努力得到了公私合营伙伴关系和联邦资助的支持，突显了公司对扩展其治疗管线和满足未满足医疗需求的承诺。</p>
</div><p>In summary, the earnings call for MiNK Therapeutics, Inc. conveyed a positive outlook, driven by successful clinical trials, strategic partnerships, and strong leadership. Despite an increase in net loss, the company’s financial strategy and ongoing advancements suggest a promising future for its innovative therapies.</p>
<div class="lb-trans"><p>总之，MiNK Therapeutics, Inc. 的财报电话会议传达了积极的前景，得益于成功的临床试验、战略合作和强大的领导力。尽管净亏损有所增加，但公司的财务战略和持续进展表明其创新疗法的未来充满希望。</p>
</div>

MiNK Therapeutics 财报电话会议：积极的市场情绪和光明的未来